Skip to main navigation
Skip to search
Skip to main content
Tel Aviv University Home
Update Request & User Guide (TAU staff only)
Home
Experts
Research units
Research output
Datasets
Prizes
Activities
Press/Media
Search by expertise, name or affiliation
[The verge and the abyss: tiotropium (Spiriva) in COPD].
Michael J. Segel
*
,
Issahar Ben-Dov
*
Corresponding author for this work
Internal Medicine
Clinical Departments
Research output
:
Contribution to journal
›
Article
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of '[The verge and the abyss: tiotropium (Spiriva) in COPD].'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Verge
100%
Chronic Obstructive Pulmonary Disease
100%
Spiriva
100%
Tiotropium
100%
Overall Mortality
28%
Israel
14%
Evidence Support
14%
Reduced Frequency
14%
Meta-analysis
14%
Adverse Effects
14%
Continued Use
14%
Treatment Group
14%
Quality of Life Improvement
14%
Beneficial Effects
14%
Cardiovascular Risk
14%
Ministry of Health
14%
Cardiovascular Mortality
14%
Cardiovascular Events
14%
Dyspnea
14%
Hospital Admission
14%
Stroke Risk
14%
U.S. Food
14%
Enhanced Response
14%
Placebo-controlled Trial
14%
Exercise Tolerance
14%
Chronic Obstructive Pulmonary Disease Patient
14%
β-adrenergic Agonist
14%
Safety Data
14%
Safety Monitoring
14%
Singh
14%
Anticholinergic Bronchodilators
14%
Long-acting Anticholinergic
14%
Bronchodilator Effect
14%
Severe Chronic Obstructive Pulmonary Disease
14%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Obstructive Lung Disease
100%
Tiotropium Bromide
100%
Bronchodilating Agent
40%
Placebo
20%
Adverse Event
20%
Cerebrovascular Accident
20%
Cardiovascular Mortality
20%
Cholinergic Receptor Blocking Agent
20%
Dyspnea
20%
Beta Adrenergic Receptor Stimulating Agent
20%
Treatment Group
20%